Congress has been closely investigating the problem of skyrocketing prescription drug costs and pricing practices. As a result, pharmaceutical drug manufacturers are ramping up their lobbying efforts this year. Pharmaceutical Research and Manufacturers of America (PhRMA) represents 37 of the countries’ biopharmaceutical research companies and has...

The 340B Drug Discount Program has faced numerous attempts at regulatory changes in the last five years; one, in particular, challenged the Orphan Drug rule. The ruling stipulated that manufacturers are not required to provide covered entities orphan drugs under 340B, but a manufacturer may, at...

Medicare patients could save an estimated $150 million on out-of-pocket co-payments for clinic visits if proposed changes to the hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Cancer (ASC) payment system are supported by the Centers for Medicare & Medicaid Services (CMS) for 2019. The...

In June, the Director of HRSA’s Office of Pharmacy Affairs, Captain Krista Pedley, testified before the U.S. Senate Committee On Health, Education, Labor, and Pensions. In her testimony, she stated, “Specific legislative authority to conduct rulemaking for all provisions in the 340B statute would be...

Despite multiple delays, the Secretary of Health and Human Services, Alex Azar, recently renewed his agencies plan to release regulations for setting 340B drug discount program drug prices. While speaking to the hospital trade group, 340B Health, Azar addressed the provider’s concerns that the multiple delays...

Prescription drug prices continue to rise and have become one the most important healthcare issues facing the nation. In an effort to address the problem, President Trump announced his drug pricing plan on May 11. After his remarks, analysts are concerned that it could significantly...